金达威：公司及子公司取得“羰基还原酶突变体”发明专利

Core Viewpoint - The company and its subsidiaries have been granted a patent for an invention related to carbonyl reductase mutants and their applications, which is expected to enhance technological innovation and core competitiveness, although it will not have a significant impact on production and operations [1] Group 1 - The patent granted is for the invention titled "Carbonyl Reductase Mutant and Its Preparation Method, Application, and Preparation Method of ®-6-Hydroxy-8-Chlorooctanoic Acid Ethyl Ester" [1] - The patent number is ZL202211709938.1, with a validity period of 20 years [1] - The official announcement date of the patent is January 30, 2026 [1] Group 2 - The patent is expected to contribute to technological innovation within the company [1] - The patent will enhance the company's core competitiveness in the industry [1] - The company does not anticipate any major impact on its production and operations from this patent [1]